| Market Cap | 4.58M | P/E | - | EPS this Y | 64.60% | Ern Qtrly Grth | - |
| Income | -8.68M | Forward P/E | 0.13 | EPS next Y | 307.70% | 50D Avg Chg | -18.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -48.00% |
| Dividend | N/A | Price/Book | 0.40 | EPS next 5Y | - | 52W High Chg | -79.00% |
| Recommedations | - | Quick Ratio | 3.09 | Shares Outstanding | 860.72K | 52W Low Chg | 3.00% |
| Insider Own | 5.89% | ROA | -61.07% | Shares Float | 547.83K | Beta | 1.44 |
| Inst Own | 2.56% | ROE | -126.86% | Shares Shorted/Prior | 17.06K/17.57K | Price | 2.53 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 501,104 | Target Price | 36.00 |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 36,034 | Change | -5.60% |
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
| HC Wainwright & Co. | Buy | May 14, 24 |
| HC Wainwright & Co. | Buy | Feb 6, 24 |
| HC Wainwright & Co. | Buy | Aug 16, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ferrara Robert L | Director Director | Jun 14 | Buy | 3.10 | 2,000 | 6,200 | 6,000 | 06/15/23 |
| Bitterman Robert J | Interim Executive Ch.. Interim Executive Chairman | Dec 14 | Buy | 0.39 | 2,000 | 780 | 74,541 | 12/15/22 |
| Bitterman Robert J | Interim Executive Ch.. Interim Executive Chairman | Dec 05 | Buy | 0.43 | 2,000 | 860 | 70,541 | 12/06/22 |
| Bitterman Robert J | Interim Executive Ch.. Interim Executive Chairman | Nov 25 | Buy | 0.41 | 2,715 | 1,113 | 68,541 | 11/29/22 |
| Ferrara Robert L | Director Director | Nov 23 | Buy | 0.4099 | 2,000 | 820 | 25,000 | 11/28/22 |
| Bitterman Robert J | Interim Executive Ch.. Interim Executive Chairman | Nov 16 | Buy | 1750.00 | 1 | 1,750 | 1 | 11/16/22 |